Monosemptomatik enürezis nokturnası olan çocuklarda desmopressin tedavi sonuçlarını etkileyen faktörler

Yıl 2025, Cilt: 15 Sayı: 3, 277 - 282, 15.09.2025

Metin Savun , Arif Kalkanlı , Emre Kandemir , Fatih Yanaral

Öz

Amaç: Desmopressin monosemptomatik enürezis nokturna tedavisinde kullanılır. Ancak, desmopressin tedavisinin başarısını etkileyen faktörlere ilişkin veriler yetersizdir. Bu çalışma, monosemptomatik enürezis nokturnası olan çocuklarda desmopressin tedavisinin sonuçlarını etkileyen faktörleri değerlendirmeyi amaçlamaktadır.

Gereç ve Yöntem: Bu çalışmaya, primer monosemptomatik enürezis nokturnası olan beş yaş üstü toplam 115 çocuk dahil edildi. Tüm hastalara günlük 120 mg desmopressin tedavisi uygulandı. Üç aylık tedaviden sonra hastalar iki gruba ayrıldı: 1. grup (başarılı) kuruluğa ulaşan çocukları içerirken, 2. grup (başarısız) tedaviye rağmen yatak ıslatmaya devam edenleri içeriyordu. Desmopressin tedavisinin başarısını etkileyen faktörler değerlendirildi.

Bulgular: Ortalama anne yaşı, grup 1'de grup 2'ye kıyasla önemli ölçüde daha yüksekti (34,8'e karşı 32,4 yıl, p = 0,044). Haftada enüretik gece sayısı ve gece başına enürezis atakları Grup 2'de önemli ölçüde daha fazlaydı (6,8'e karşı 6 gece, p = 0,030; 1,7'ye karşı 1,4 atak, p = 0,040). Çok değişkenli analiz, 33 yaş üstü annelere sahip çocukların desmopressin tedavisine yanıt verme olasılığının 3,5 kat daha fazla olduğunu ortaya koydu (olasılık oranı: 3,5 [1,2-10,5], p = 0,023).

Sonuç: Desmopressin tedavisinin başarısını etkileyen faktörler; anne yaşı, haftada enüretik gece sayısı ve gece başına enürezis sayısı olarak bulundu. Bunlar arasında, anne yaşı tedavi sonuçlarının tek bağımsız öngörücüsü olarak bulundu.

Anahtar Kelimeler

Deamino Arginin Vazopressin , Dezmopressin , enürezis , monosemptomatik gece idrar kaçırma , noktürnal enürezis

Factors influencing desmopressin treatment outcomes in children with monosymptomatic enuresis nocturna

Öz

Aim: Desmopressin has been used in to treatment of monosymptomatic enuresis nocturna. However, data on the factors affecting desmopressin treatment success remain insufficient. This study aimed to evaluate the factors that influence desmopressin treatment outcomes in children with monosymptomatic enuresis nocturna.

Material and Methods: A total of 115 children aged over five years with primary monosymptomatic enuresis nocturna were included in this study. All patients were treated with 120 mg desmopressin daily. After three months of treatment, the patients were divided into two groups: group 1 (successful) included children who achieved dryness, while group 2 (unsuccessful) comprised those who continued bedwetting despite treatment. Factors influencing the success of desmopressin treatment were evaluated.

Results: The mean maternal age was significantly higher in group 1 compared to group 2 (34.8 vs. 32.4 years, p = 0.044). The number of enuretic nights per week and enuresis episodes per night were significantly greater in Group 2 (6.8 vs. 6 nights, p = 0.030; 1.7 vs. 1.4 episodes, p = 0.040). Multivariate analysis revealed that children with mothers aged over 33 years were 3.5 times more likely to respond to desmopressin treatment (odds ratio: 3.5 [1.2-10.5], p = 0.023).

Conclusion: Factors influencing desmopressin treatment success included maternal age, frequency of enuretic nights per week, and the number of enuresis episodes per night. Among these, maternal age was identified as the only independent predictor of treatment outcomes.

Anahtar Kelimeler

Deamino Arginine Vasopressin , Desmopressin , Enuresis , monosymptomatic enuresis nocturna , Nocturnal Enuresis

Kaynakça

• 1. Austin PF, Bauer SB, Bower W, Chase J, Franco I, Hoebeke P et al. The standardization of terminology of lower urinary tract function in children and adolescents: Update report from the standardization committee of the International Children's Continence Society. Neurourol Urodyn. 2016;35(4):471-81.
• 2. The ICD-10 classification of mental and behavioral disorders in children and adolescents: ISBN 92-4-154422-8. World Health Organization, Geneva, Switzerland. 2008;38-9
• 3. Sharma N, Mishra R, Mishra D. The fifth edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-5): what is new for the pediatrician? Indian Pediatr. 2015;52(2):141-3.
• 4. Arda E, Cakiroglu B, Thomas DT. Primary nocturnal enuresis: a review. Nephro-urology monthly 2016;8(4),1-6.
• 5. Deshpande AV, Caldwell PH. Medical management of nocturnal enuresis. Pediatr drugs 2012;14(2),71-7.
• 6. Walker RA. Nocturnal Enuresis. Prim Care 2019;46(2),243-8.
• 7. Jain S, Bhatt GC. Advances in the management of primary monosymptomatic nocturnal enuresis in children. Paediatr Int Child H 2016;36(1),7-14.
• 8. Song P, Huang C, Wang Y, Wang Q, Zhu W, Yue Y et al. Comparison of desmopressin, alarm, desmopressin plus alarm, and desmopressin plus anticholinergic agents in the management of paediatric monosymptomatic nocturnal enuresis: a network meta-analysis. BJU Int. 2019;123(3):388-400.
• 9. Kamperis K, Van Herzeele C, Rittig S, Walle JV. Optimizing response to desmopressin in patients with monosymptomatic nocturnal enuresis. Pediatr Nephrol, 2017;32(2), 217-26.
• 10. Forsythe WI, Redmond A. Enuresis and spontaneous cure rate: study of 1129 enuretics. Arch Dis Child 1974;49:259–63.
• 11. Van Herzeele C, Evans J, Eggert P, Lottmann H, Norgaard JP, Walle JV. Predictive parameters of response to desmopressin in primary nocturnal enuresis. J Ped Urol, 2015;11(4),200-e1.
• 12. Montaldo P, Tafuro L, Rea M, Narciso V, Iossa AC, Gado RD. Desmopressin and oxybutynin in monosymptomatic nocturnal enuresis: a randomized, double blind, placebo controlled trial and an assessment of predictive factors. BJU Int 2012;110(8b), E381-6.
• 13. Kruse S, Hellstrom AL, Hanson E, Hjälmås K, Sillén U. Swedish Enuresis Trial (SWEET) Group Treatment of primary mono symptomatic nocturnal enuresis with desmopressin: predictive factors. Br J Urol 2001;88(6):572–6
• 14. Yanaral F, Eroğlu A, Çilesiz NC, Gezmiş CT, Tandoğdu Z, Balcı MBC et al. Evaluation of Etiological Risk Factors of Primary Monosymptomatic Enuresis. J Acad Res Med 2019;9(3),102-6.
• 15. Järvelin MR, Vikeväinen-Tervonen L, Moilanen I, Huttunen NP. Enuresis in seven-year-old children. Acta Paediatr Scand 1988;77(8): 148–53.
• 16. Tai TT, Tai BT, Chang YJ, Huang KH. The Importance of Understanding Parental Perception When Treating Primary Nocturnal Enuresis: A Topic Review and an Institutional Experience. Res Rep Urol. 2021;13:679-90.
• 17. Yitik Tonkaz G, Deliağa H, Çakir A, Tonkaz G, Özyurt G. An evaluation of parental attitudes and attachment in children with primary monosymptomatic nocturnal enuresis: A case-control study. J Pediatr Urol. 2023;19(2):174.e1-5.
• 18. Schlomer B, Rodriguez E, Weiss D, Copp H. Parental beliefs about nocturnal enuresis causes, treatments, and the need to seek professional medical care. J Pediatr Urol. 2013;9(6 Pt B):1043-8.
• 19. Onol FF, Guzel R, Tahra A, Kaya C, Boylu U. Comparison of longterm efficacy of desmopressin lyophilisate and enuretic alarm for monosymptomatic enuresis and assessment of predictive factors for success: a randomized prospective trial. J Urol 2015;193(2), 655-61.
• 20. Sancak EB, Oguz U, Aykac A, Demirelli E, Bozkurt OF, Cimen S. The effect of breastfeeding on spontan resolution of monosymptomatic enuresis. Int Braz J Urol, 2016;42(3),550-7.